Paraneoplastic Cerebellar Degeneration (PCD): A Comprehensive Disease Characteristics Report

MONDO ID: MONDO:0044877 · Category: Complex (immune-mediated, non-Mendelian) Report type: Disease knowledge-base synthesis from literature (69 papers reviewed; 12 confirmed findings) Evidence base: Human clinical cohorts and case series, model-organism studies, in vitro immunology

Summary

Paraneoplastic cerebellar degeneration (PCD) is a rare, immune-mediated, subacute pancerebellar syndrome that arises as a remote effect of cancer. It is not a genetic disease in the Mendelian sense; instead, the initiating lesion is a malignancy that ectopically expresses a neuronal ("onconeural") antigen normally restricted to cerebellar Purkinje cells. This aberrant expression breaks immune tolerance in genetically predisposed (HLA Class II) hosts, triggering an anti-tumor immune response that cross-reacts with the cerebellum. The dominant effector mechanism is cytotoxic CD8+ T-cell-mediated destruction of Purkinje cells, with autoantibodies serving primarily as diagnostic biomarkers rather than the direct cause of neuronal death (for the intracellular-antigen subtypes). The clinical result is subacute (weeks-to-months) progressive gait and limb ataxia, dysarthria, nystagmus, and dizziness, typically plateauing within ~6 months, often leaving patients severely and irreversibly disabled.

The single most important organizing principle to emerge from this investigation is the antigen-location prognosis rule: antibodies against intracellular antigens (anti-Yo/CDR2, anti-Hu/ANNA-1, Ma2) mark a T-cell-driven, largely irreversible process with poor neurological outcomes, whereas antibodies against cell-surface antigens (anti-DNER/Tr, anti-mGluR1) mark a more antibody-mediated, treatment-responsive process. Anti-Yo (PCA-1), directed against CDR2/CDR2L, is the most common variant, occurring almost exclusively in women with gynecologic or breast cancer, and carries a dismal prognosis (≈84% of survivors unable to walk unassisted). Anti-Tr/DNER PCD, by contrast, occurs mostly in middle-aged men with Hodgkin lymphoma and is more treatable.

Management rests on two pillars applied urgently: prompt tumor detection and treatment (antibody-guided screening, with FDG-PET/CT central when conventional imaging is negative) and immunotherapy (corticosteroids, IVIG, plasma exchange, cyclophosphamide, rituximab). Good outcomes correlate with early diagnosis, low disability at presentation (mRS <3), absence of metastasis, and combined immunotherapy plus tumor-directed therapy. An emerging iatrogenic trigger is the class of immune checkpoint inhibitors (ICIs), which can unmask or amplify pre-existing onconeural immunity. Population data indicate PCD is the second most common paraneoplastic neurological syndrome (≈28% of PNS), against an overall PNS incidence of ~0.89/100,000 person-years.

Section 1 — Disease Information

Overview. PCD is an autoimmune cerebellar syndrome triggered by an underlying (often occult) malignancy. It belongs to the broader family of paraneoplastic neurological syndromes (PNS) and immune-mediated cerebellar ataxias (IMCAs). The typical presentation is "the subacute development of pancerebellar deficits with a clinical plateau within 6 months" (PMID: 27606347).

Key identifiers. - MONDO: MONDO:0044877 - MeSH: Paraneoplastic Cerebellar Degeneration - ICD-10: G13.1 (Systemic atrophy primarily affecting central nervous system in neoplastic disease) / D48.9 with paraneoplastic manifestation - Orphanet: Paraneoplastic cerebellar degeneration (rare neurological PNS) - OMIM: Not applicable — PCD is not a heritable Mendelian disorder; no OMIM disease entry (relevant onconeural genes have Gene OMIM entries, e.g., CDR2).

Synonyms / alternative names. Paraneoplastic cerebellar degeneration; subacute cerebellar degeneration (paraneoplastic); anti-Yo/PCA-1 cerebellar ataxia (for that subtype); paraneoplastic cerebellar ataxia; onconeural cerebellar syndrome. Antibody-defined subtypes: PCA-1 (anti-Yo), PCA-Tr (anti-Tr/DNER), ANNA-1 (anti-Hu), ANNA-2 (anti-Ri), PCA-2 (anti-MAP1B).

Information source type. This report is derived from aggregated disease-level resources — systematic reviews, laboratory serology cohorts (Mayo Clinic, Barcelona), population-based epidemiology, and case series — rather than from individual EHR patient records.

Section 2 — Etiology

Primary cause. The causal factor is an underlying malignancy that ectopically expresses a neuronal antigen. In anti-Yo disease, "the Yo autoantibodies are directed against the Yo antigens, aberrantly overexpressed by tumor cells with frequent somatic mutations and gene amplifications" (PMID: 38494293). The disease is therefore fundamentally a cancer-triggered autoimmune process, not genetic, environmental (toxic), or infectious in origin.

Tumor-type risk factors (antibody-dependent). - Anti-Yo → gynecologic (ovarian, endometrial) and breast carcinoma; 96% female, 82% gynecologic cancer (PMID: 36334195). - Anti-Tr/DNER → Hodgkin lymphoma, middle-aged males (PMID: 34817790). - Anti-Hu, CV2/CRMP5, PCA-2/MAP1B, ZIC4 → small-cell lung cancer (SCLC), often in smokers. - Anti-Ma2 → testicular germ-cell tumors (young men <50), also lung/breast.

Genetic risk factors. Host susceptibility is conferred by HLA Class II haplotypes rather than causal coding mutations. High-resolution typing of 40 anti-Yo cases identified protective haplotypes (DPA1*01:03~DPB1*04:01, OR=0, p=0.0008) and an ovarian-cancer-specific susceptibility haplotype (DRB1*13:01~DQA1*01:03~DQB1*06:03, OR=5.4, p=0.0016), indicating "differential genetic susceptibility to anti-Yo per cancer and with a primary HLA Class II involvement" (PMID: 29306402).

Environmental / lifestyle risk factors. Tobacco smoking is a strong indirect risk factor via SCLC-associated subtypes (anti-Hu, CRMP5). No direct toxic, occupational, or infectious cause of PCD itself is established.

Iatrogenic trigger. Immune checkpoint inhibitors (anti-PD-1/PD-L1/CTLA-4) are an emerging cause; they can "amplify pre-existing onconeural immunity" (PMID: 42442848).

Protective factors. The only clearly documented protective factors are the HLA Class II protective haplotypes above. No dietary or lifestyle protective factors are established.

Gene–environment interaction. The model is: a tumor (environmental/somatic event) expressing an onconeural antigen, in a host carrying a permissive/susceptible HLA Class II genotype, produces tolerance breakdown. Molecular mimicry directs the specificity, and co-signaling molecules (checkpoint pathways) modulate the strength — a concept reinforced by the ICI-triggered cases (PMID: 39052041).

Section 3 — Phenotypes

The core phenotype is a subacute, progressive pancerebellar syndrome (HPO: HP:0001251 Ataxia; HP:0002070 Limb ataxia; HP:0002066 Gait ataxia).

Characteristics. Onset is adult/late-adult (median age ~60 for anti-Yo, ~68 in the population PNS cohort). Course is subacute and progressive over weeks to months, with "a clinical plateau within 6 months" (PMID: 27606347). Severity is typically severe for intracellular-antigen subtypes: despite treatment, 84% of anti-Yo survivors are unable to walk unassisted at follow-up (PMID: 36334195). "Vertigo and imbalance can be present early in the disease course in about two thirds of patients, as a prodromal phase" (PMID: 36334195).

Quality-of-life impact. Profound — most patients with intracellular-antigen PCD become wheelchair-dependent, non-ambulatory, and dependent for activities of daily living, with dysarthria impairing communication. Surface-antigen subtypes may recover substantially.

Extracerebellar features. Rare in isolated anti-Tr/DNER PCD (8%) (PMID: 34817790); anti-Hu and anti-Ma2 more often present with multifocal encephalomyelitis, limbic/brainstem involvement, and peripheral neuropathy.

Section 4 — Genetic / Molecular Information

PCD has no causal germline disease gene. The relevant molecules are the onconeural target antigens and the host HLA Class II susceptibility loci.

Onconeural antigens (target autoantigens).

The anti-Yo antigen designation and target are established: anti-Yo is "directed against cerebellar degeneration-related protein 2 (CDR2) and CDR2L" and is "the most common variant of paraneoplastic cerebellar degeneration" (PMID: 27606347). Anti-Tr binds "the extracellular domain of DNER" (PMID: 25745634).

Somatic vs germline. The genetic aberrations are somatic in the tumor — "aberrantly overexpressed by tumor cells with frequent somatic mutations and gene amplifications" of the Yo antigen genes (PMID: 38494293). There is no germline pathogenic variant driving PCD.

Modifier genes / functional consequences. HLA Class II haplotypes modify susceptibility per cancer type (PMID: 29306402). Epigenetic and chromosomal abnormality data specific to PCD are not established beyond tumor-level somatic changes.

HGNC / Gene identifiers: CDR2 (HGNC:1802), CDR2L (HGNC:14002), ELAVL4/HuD, PNMA2, DPYSL5/CRMP5, MAP1B, GRM1, DNER, HOMER3, ZIC4.

Section 5 — Environmental Information

• Environmental/toxic factors: No direct environmental toxin causes PCD. The relevant "environmental" exposure is tobacco smoke, acting indirectly by causing SCLC (the tumor substrate for anti-Hu, CRMP5, PCA-2, ZIC4 subtypes).
• Lifestyle factors: Smoking (via SCLC). No dietary triggers established.
• Infectious agents: None causative. PCD is a paraneoplastic (tumor-driven) autoimmune process, though molecular mimicry conceptually parallels post-infectious immune cerebellar ataxias in the broader IMCA family (PMID: 39052041).
• Iatrogenic: Immune checkpoint inhibitor therapy (see Sections 2, 6, 12).

Section 6 — Mechanism / Pathophysiology

Ordered causal chain

1. A malignancy arises (e.g., ovarian/breast carcinoma, SCLC, Hodgkin lymphoma) and, through somatic mutation/gene amplification, ectopically expresses an onconeural antigen (CDR2/CDR2L, HuD, DNER, Ma2) normally restricted to neurons → results in presentation of a neural self-antigen to the immune system in an immunogenic (tumor) context (PMID: 38494293).
2. In a host carrying permissive HLA Class II haplotypes, this ectopic antigen presentation leads to breakdown of immune self-tolerance (PMID: 29306402).
3. Tolerance breakdown results in an anti-tumor adaptive immune response: generation of onconeural autoantibodies AND antigen-specific T cells. (For surface antigens, the branch is antibody-dominant; for intracellular antigens, the branch is T-cell-dominant — see branch below.)
4. Intracellular-antigen branch (Yo, Hu, Ma2): cross-reactive cytotoxic CD8+ T lymphocytes (CTLs) traffic across the blood–brain barrier into the CSF/cerebellum → leads to antigen recognition of Purkinje cells → results in CTL-mediated Purkinje cell apoptosis/death (PMID: 10632096; PMID: 9879687). Antibody alone is insufficient to cause degeneration (inferred from failed passive-transfer/immunization models) (PMID: 7707074; PMID: 7788981).
5. Surface-antigen branch (DNER, mGluR1): autoantibodies bind the extracellular domain of the target → results in receptor dysfunction/internalization that is potentially reversible → more treatment-responsive disease (PMID: 25745634; PMID: 41197574).
6. Purkinje cell loss leads to loss of the sole output neuron of the cerebellar cortex → results in pancerebellar dysfunction (gait/limb ataxia, dysarthria, nystagmus).
7. Progressive Purkinje depletion leads to cerebellar atrophy (radiographically visible late) and, for intracellular subtypes, irreversible clinical disability (PMID: 27606347).

 Tumor (ectopic onconeural antigen: CDR2/CDR2L, HuD, DNER, Ma2)
            │  (somatic mutation/amplification)
            ▼
 HLA Class II–permissive host  ──►  Tolerance breakdown
            │
   ┌────────┴─────────┐
   ▼                  ▼
 INTRACELLULAR Ag    SURFACE Ag
 (Yo, Hu, Ma2)       (DNER, mGluR1)
   │                  │
 CD8+ CTL response   Antibody binds
 (dominant)          extracellular domain
   │                  │
 Purkinje-cell        Receptor dysfunction
 cytotoxic killing    (± reversible)
   │                  │
 IRREVERSIBLE  ◄──── vs ────►  TREATMENT-RESPONSIVE
 disability                    recovery
   │
   ▼
 Purkinje cell loss → pancerebellar syndrome → cerebellar atrophy

Molecular pathways / cellular processes. Adaptive immunity: MHC Class I/II antigen presentation, T-cell receptor engagement, CTL granule-mediated cytotoxicity, apoptosis (GO:0006915), and antigen-specific B-cell/plasma-cell antibody production. In active PCD CSF, ">75% of cells were CD3+ alphabeta T cells and 20–40% were activated T cells," and "activated cdr2-specific CTLs in the CSF contribute to Purkinje degeneration in PCD" (PMID: 10632096). CASPR2-associated cerebellar ataxia similarly shows combined CD8+ T-cell and CD138+ plasma-cell CSF infiltration (PMID: 22759321).

Protein dysfunction. For intracellular antigens the antigen is a normal neuronal protein (loss of Purkinje cells eliminates its function); for surface antigens (DNER, a Notch-pathway EGF-repeat receptor; mGluR1, essential for motor coordination/learning), antibody binding impairs signaling. Notably Homer-3's partner mGluR1A "is predominantly expressed in Purkinje cells where its function is essential for motor coordination and motor learning" (PMID: 35871640).

Immune system involvement. Central and defining — a cell-mediated (CTL) plus humoral autoimmune attack. Autoantibodies of multiple immunoglobulin classes bind Purkinje cytoplasm across species (PMID: 3346369).

Suggested GO / CL terms. GO:0006915 (apoptotic process), GO:0002456 (T cell mediated immunity), GO:0001913 (T cell mediated cytotoxicity), GO:0002376 (immune system process), GO:0019882 (antigen processing and presentation). CL: CL:0000121 (Purkinje cell — primary target), CL:0000794 (CD8-positive, alpha-beta cytotoxic T cell — effector), CL:0000786 (plasma cell), CL:0000909 (CD8-positive alpha-beta memory T cell).

Section 7 — Anatomical Structures Affected

• Primary organ / system: Central nervous system — the cerebellum (UBERON:0002037), specifically the cerebellar cortex (UBERON:0002129).
• Primary cell target: Purkinje cells (CL:0000121; UBERON: Purkinje cell layer UBERON:0002974). Purkinje-cell loss is the pathological hallmark; molecular-layer interneurons are also stained by autoantibodies (PMID: 3346369).
• Secondary involvement: Brainstem, limbic system, diencephalon, and peripheral nerves in overlap syndromes (anti-Hu encephalomyelitis, anti-Ma2 limbic/diencephalic/brainstem encephalitis, anti-Ri brainstem syndrome).
• Tissue type: Nervous tissue.
• Subcellular compartments: Depends on antigen — cytoplasm (CDR2/CDR2L; GO:0005737), nucleus (HuD, Ri; GO:0005634), plasma membrane / cell surface (DNER, mGluR1; GO:0005886), postsynaptic density (Homer-3; GO:0014069).
• Localization / lateralization: Bilateral, symmetric cerebellar involvement is typical (pancerebellar). FDG-PET may show bilateral cerebellar hypometabolism (early) or hyperperfusion in some inflammatory cases.

Section 8 — Temporal Development

• Onset: Adult to older-adult (median ~60–68 years). Onset pattern is subacute — evolving over weeks to a few months.
• Prodrome: Vertigo/imbalance precedes the full syndrome in ~two-thirds of anti-Yo patients (PMID: 36334195).
• Progression: Rapidly progressive during the active phase, then plateaus within ~6 months (PMID: 27606347), after which deficits are usually fixed (intracellular subtypes). Cerebellar atrophy appears late on MRI.
• Course pattern: Monophasic progressive-then-plateau for classic onconeural PCD; surface-antigen cases may relapse or remit with immunotherapy.
• Duration: Chronic/lifelong disability once the plateau is reached in intracellular-antigen disease.
• Critical window: There is a narrow therapeutic window before irreversible Purkinje loss; "early tumor detection, diagnosis, and PCD treatment are essential because any delay can result in the progression of the disorder and irreversible neurological damage" (PMID: 35501715).
• Tumor timing: The neurological syndrome usually precedes cancer diagnosis; screening should be repeated over time (tumors may surface years later) (PMID: 22157026).

Section 9 — Inheritance and Population

• Epidemiology: In a population-based 9-year Italian study (983,190 people), overall PNS incidence was 0.89/100,000 person-years and prevalence 4.37/100,000; "PNS developed in 1 in every 334 cancers" (PMID: 31552550). Cerebellar degeneration was the second most common PNS at 28% (after limbic encephalitis 31%): "Most common PNS were limbic encephalitis (31%), cerebellar degeneration (28%) and encephalomyelitis (20%)" (PMID: 31552550). Antibody specificities in that cohort: Yo 30%, Hu 26%, Ma2 22%; associated tumors lung 17%, breast 16%, lymphoma 12%.
• Inheritance: Not heritable — PCD is acquired/autoimmune. The only genetic contribution is HLA Class II susceptibility (polygenic/multifactorial predisposition), not a Mendelian inheritance pattern.
• Penetrance / expressivity / anticipation / mosaicism / founder effects / consanguinity / carrier frequency: Not applicable (no causal germline mutation).
• Sex ratio: Strongly subtype-dependent. Anti-Yo: 96% female (PMID: 36334195). Anti-Tr/DNER: predominantly middle-aged males (PMID: 34817790). Anti-Ma2: predominantly young males (testicular tumors). Overall PNS cohort ~52% female, median age 68 (PMID: 31552550).
• Age distribution: Adult/older adult, tracking the age of the underlying cancers.

Section 10 — Diagnostics

Clinical / CSF. CSF is frequently inflammatory: "lymphocytic pleocytosis, elevated protein, elevated IgG index, and oligoclonal bands" (PMID: 27606347; PMID: 35871640).

Antibody testing (the diagnostic cornerstone). Serum and CSF onconeural antibody panels: anti-Yo/CDR2/CDR2L, anti-Hu, anti-Ri, anti-Tr/DNER, anti-Ma2, anti-CV2/CRMP5, anti-PCA-2/MAP1B, anti-mGluR1, anti-Homer-3, anti-ZIC4. The anti-Tr/DNER recombinant cell-based assay reaches 100% sensitivity/specificity (PMID: 25745634). Rodent cerebellar tissue reliably reproduces the diagnostic Purkinje-cytoplasm immunostaining (PMID: 3346369).

Imaging. "Magnetic resonance imaging of the brain is often normal in the early stages, with cerebellar atrophy seen later" (PMID: 27606347). FDG-PET can show cerebellar hypometabolism.

Tumor screening (antibody-guided, time-critical). Per the EFNS task force, "the nature of antibody, and to a lesser extent the clinical syndrome, determines the risk and type of an underlying malignancy," and "for screening of the thoracic region, a CT-thorax is recommended, which if negative is followed by fluorodeoxyglucose-positron emission tomography (FDG-PET)" (PMID: 20880069). FDG-PET/CT detected malignancy in ~19% of suspected PNS patients and is recommended regardless of antibody status (PMID: 22157026). Screening should be repeated if initially negative, because the tumor usually postdates neurological onset.

Diagnostic criteria. The 2021 updated PNS diagnostic criteria replaced "classical syndromes" with "high-risk phenotypes," reclassified antibodies as high-risk (>70% cancer association) vs intermediate-risk (30–70%), and introduced the PNS-Care Score combining phenotype, antibody, cancer presence, and follow-up to grade diagnoses as definite/probable/possible (PMID: 34006622).

Differential diagnosis. Hereditary/degenerative ataxias, multiple system atrophy (cerebellar type), toxic/metabolic cerebellar injury, gluten ataxia, anti-GAD ataxia, post-infectious cerebellitis, primary autoimmune cerebellar ataxia (PACA), and metastatic/leptomeningeal disease (PMID: 39052041; PMID: 35618871).

Section 11 — Outcome / Prognosis

Antigen-location prognosis rule (central finding). Intracellular-antigen antibodies (Yo, Hu) predict irreversible disability; surface-antigen antibodies (DNER, mGluR1) predict a treatable course. In anti-Yo disease, despite treatment, 84% of survivors are unable to walk unassisted at follow-up (PMID: 36334195). In anti-mGluR1 cerebellar syndrome, "the majority of patients showed clinical improvement (n = 31)" of 42 (PMID: 41197574).

Predictors of good outcome. In a 97-patient PNS cohort with good outcome in 54.6%, "factors associated with good outcome were: early diagnosis, mRS <3 at presentation, absence of metastatic disease, and adjuvant immunotherapy" (PMID: 33911377).

Oncologic paradox. PNS can prompt earlier cancer detection, conferring a survival advantage despite neurological morbidity: ANNA1/Hu-IgG PNS + SCLC patients had "a 41% lower hazard of death" than SCLC-only patients (HR=0.59, 95% CI 0.37–0.96) (PMID: 42233990).

Subtype-specific prognosis. Anti-Ma2-only patients fare significantly better than anti-Ma (Ma1+Ma2) patients — "the clinical outcome was significantly better in the anti-Ma2 group" (PMID: 27460184). ICI-related cerebellar ataxia: 46% improved but with residual disability (PMID: 39153058). In ICI-related PNS more broadly, risk-antibody positivity carried 29% mortality vs 10% in antibody-negative patients (P=0.012) (PMID: 41488641).

Morbidity / QoL. High disability burden: wheelchair dependence, dysarthria, and loss of independence dominate the intracellular-antigen subtypes.

Section 12 — Treatment

Treatment rests on two urgent pillars: (1) prompt tumor removal/therapy and (2) immunotherapy.

Tumor-directed therapy. Surgery, chemotherapy, or radiotherapy of the underlying malignancy is the mainstay and can stabilize or improve neurological symptoms.

Immunotherapy (NCIT: Immunotherapy). - Corticosteroids / IV methylprednisolone pulses (NCIT: Methylprednisolone) - Intravenous immunoglobulin (NCIT: Intravenous Immunoglobulin Therapy) - Plasma exchange (NCIT: Plasmapheresis) — can give repeated benefit in some cases (PMID: 31142706) - Cyclophosphamide (NCIT: Cyclophosphamide) - Rituximab / anti-CD20 (NCIT: Rituximab); ofatumumab reported in refractory anti-Yo (PMID: 39737186)

Response by subtype. "Patients with surface receptor autoimmunity … usually show a good response to treatment," in contrast to classical (intracellular) onconeural PNS (PMID: 29327271). Anti-Yo/intracellular cases often deteriorate despite aggressive therapy (PMID: 35501715). Early rituximab benefited non-tumor anti-DNER (PMID: 37991702) and anti-mGluR1 (PMID: 40760473) cases.

ICI-related PCD management. Discontinue the checkpoint inhibitor and start immunosuppression; outcomes are variable, and rechallenge can provoke relapse (PMID: 37151179).

Supportive / rehabilitative. Symptomatic agents (e.g., 4-aminopyridine for downbeat nystagmus/oscillopsia) plus physical, occupational, and speech therapy.

Overall. Good outcome in ~55% when combined immunotherapy + tumor treatment is applied early (PMID: 33911377).

Section 13 — Prevention

• Primary prevention: Reducing cancer risk (e.g., smoking cessation to reduce SCLC-associated subtypes) is the only meaningful primary preventive lever; there is no vaccine or specific prophylaxis.
• Secondary prevention (most actionable): Early recognition of a subacute cerebellar syndrome, prompt antibody testing, and antibody-guided tumor screening with FDG-PET to detect and treat the malignancy before irreversible Purkinje loss (PMID: 20880069; PMID: 22157026). In known cancer survivors, PCD can herald relapse (e.g., Hodgkin lymphoma) — vigilance enables early re-treatment.
• Tertiary prevention: Immunotherapy plus rehabilitation to limit disability once disease is established.
• Pre-ICI risk stratification: Pre-treatment screening for onconeural antibodies before checkpoint-inhibitor therapy may identify high-risk patients (PMID: 41488641).
• Genetic counseling / carrier screening / immunization: Not applicable (non-heritable, non-infectious).

Section 14 — Other Species / Natural Disease

• Taxonomy: Naturally occurring PCD is essentially a human (Homo sapiens, NCBI:txid9606) disease. No well-characterized spontaneous paraneoplastic cerebellar degeneration is documented in companion animals as a defined entity.
• Related veterinary autoimmune cerebellar/encephalitic disease: Neuronal-autoantibody encephalitis is increasingly recognized in cats — including a reported case of anti-mGluR1 antibodies in a cat (PMID: 42656301) — but this was not clearly paraneoplastic.
• Orthologous genes: CDR2/CDR2L, ELAVL4/HuD, Grm1, Dner, Pnma2, Homer3 have rodent orthologs (mouse Cdr2, Grm1, Dner), enabling model work.
• Comparative pathology: Autoantibodies from human PCD sera bind Purkinje-cell cytoplasm in human, rat, and mouse cerebellum, indicating cross-species antigen conservation (PMID: 3346369).
• Zoonotic potential: None (autoimmune, non-transmissible).

Section 15 — Model Organisms

Attempts to build a faithful animal model have repeatedly failed to reproduce degeneration by antibody alone, which is itself the key mechanistic evidence for T-cell causation.

Model type: Mammalian (mouse, rat, SCID mouse) and in vitro human cellular immunology. Genetic models: immunization/transgene (DNA immunization) rather than knockout disease models. Phenotype recapitulation: Poor — antibodies and even antigen-specific CTLs can be generated without overt cerebellar degeneration, a major limitation likely reflecting incomplete CNS T-cell trafficking or additional required signals. Applications: Established that antibody is not the sole effector and pointed to CTLs; useful for diagnostic reagent validation (rodent cerebellum for immunostaining).

Mechanistic Model / Interpretation

PCD is best understood as collateral autoimmune damage from an anti-tumor immune response. The unifying model is antigenic: a tumor ectopically expresses a neuronal protein → tolerance breaks in an HLA-Class-II-permissive host → adaptive immunity attacks both tumor and cerebellum. The antigen's subcellular location dictates the effector mechanism and therefore the prognosis:

• Intracellular antigens (CDR2/CDR2L, HuD, Ma2) can only be seen by the immune system as MHC-presented peptides → CD8+ CTL cytotoxicity → Purkinje-cell death that is rapid, irreversible, and poorly antibody-treatable. The antibodies are bystander biomarkers.
• Surface antigens (DNER, mGluR1) are directly accessible to antibodies → antibody-mediated receptor dysfunction that is often reversible → treatment-responsive disease.

This single axis explains the epidemiology (tumor associations by antibody), the diagnostics (antibody-guided screening), the treatment response gradient, and the prognosis. The failed animal models are not a gap but positive evidence: they demonstrate that circulating antibody, complement, and macrophages cannot kill Purkinje cells, forcing the conclusion that the effector is the cytotoxic T cell.

Evidence Base (key literature)

Limitations and Knowledge Gaps

1. No faithful animal model of the degeneration exists; the CTL effector mechanism is inferred from failed antibody-transfer experiments plus in vitro human CTL reactivity, not from a reproducible in vivo lesion.
2. Rarity and heterogeneity limit prospective, controlled treatment data; most evidence is from case series, retrospective cohorts, and systematic reviews of case reports — susceptible to publication and referral bias (serology-lab cohorts over-represent antibody-positive cases).
3. Molecular detail of tolerance breakdown (why specific tumors over-express onconeural antigens, and the exact epitope-spreading/mimicry events) is incompletely defined.
4. Prognostic biomarkers beyond antibody class/antigen location are lacking; no validated molecular predictor of immunotherapy response.
5. Epigenetic, transcriptomic, proteomic, and single-cell profiling of PCD cerebellum are largely absent from the literature reviewed — a genuine data gap.
6. HLA association data derive from a single modest cohort (n=40); replication across ancestries is needed.

Proposed Follow-up Experiments / Actions

1. Single-cell / spatial profiling of PCD-affected cerebellum and matched CSF (CITE-seq, TCR sequencing) to define the clonality and antigen-specificity of infiltrating CD8+ T cells and confirm the CTL model in situ.
2. Humanized HLA-transgenic mouse models expressing onconeural antigens in a tumor context, with adoptive transfer of antigen-specific CD8+ T cells, to finally recapitulate Purkinje-cell loss.
3. Multi-center prospective registry with standardized PNS-Care scoring, antibody subtyping, and mRS trajectories to quantify outcomes and treatment effects by antigen location.
4. Replication of HLA Class II associations in larger, ancestrally diverse cohorts, extended to non-Yo subtypes.
5. Trials of T-cell-directed immunotherapy (e.g., agents targeting CD8+ CTLs or trafficking) for intracellular-antigen PCD, where B-cell-directed therapy underperforms.
6. Pre-ICI onconeural antibody screening protocols with prospective evaluation of whether screening plus surveillance reduces severe checkpoint-inhibitor cerebellar toxicity.
7. Biomarker discovery (CSF proteomics/neurofilament light) to identify early, treatable-window markers before irreversible atrophy.

Report compiled from 69 reviewed publications and 12 confirmed findings across 5 investigative iterations. Evidence types are labeled per claim; PMIDs link to primary sources.